PubMed
LL-37, the only human member of the cathelicidin family of antimicrobial peptides
Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012
Compare
LL-37 vs TB-500 Fragment
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
LL-37
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Self-reported dose per injection
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 100–400 mcg
100–200
4
200–400
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
TB-500 Fragment
26 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
176
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
171
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 1 to ≥ 2 mg (open-ended top bucket)
1–2 mg
59
2+ mg
117
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 79% said they felt similar to their last entry, 21% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 188 days · Based on 24 repeat reporters
Sources (8)
Published sources linked on the LL-37 and TB-500 Fragment wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
The antimicrobial peptide LL-37 inhibits biofilm formation
Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011
- Wiki study page →Source
ClinicalTrials.gov
LL-37 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Rosacea: Pathogenesis and Therapeutic Correlates
Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024
- Wiki study page →Source
PubMed
LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review
Soman D, P J, Cm M, et al. Archives of oral biology. 2026
- Wiki study page →Source
PubMed
Thymosin beta4: a multi-functional regenerative peptide (review)
Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012
- Wiki study page →Source
PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
- Wiki study page →Source
PubMed
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026